MCID: ATR011
MIFTS: 69

Atrial Fibrillation

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Atrial Fibrillation

MalaCards integrated aliases for Atrial Fibrillation:

Name: Atrial Fibrillation 12 38 30 56 6 44 3 45 15 64 64 17 74
Fibrillation, Atrial 41
a-Fib 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060224
KEGG 38 H00731
ICD9CM 36 427.31
MeSH 45 D001281
NCIt 51 C50466
SNOMED-CT 69 49436004
UMLS 74 C0004238

Summaries for Atrial Fibrillation

PubMed Health : 64 About atrial fibrillation: Atrial fibrillation (A-tre-al fi-bri-LA-shun), or AF, is the most common type of arrhythmia (ah-RITH-me-ah). An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm.AF occurs if rapid, disorganized electrical signals cause the heart's two upper chambers—called the atria (AY-tree-uh)—to fibrillate. The term "fibrillate" means to contract very fast and irregularly.In AF, blood pools in the atria. It isn't pumped completely into the heart's two lower chambers, called the ventricles (VEN-trih-kuls). As a result, the heart's upper and lower chambers don't work together as they should.People who have AF may not feel symptoms. However, even when AF isn't noticed, it can increase the risk of stroke. In some people, AF can cause chest pain or heart failure, especially if the heart rhythm is very rapid.AF may happen rarely or every now and then, or it may become an ongoing or long-term heart problem that lasts for years.

MalaCards based summary : Atrial Fibrillation, also known as fibrillation, atrial, is related to familial atrial fibrillation and congestive heart failure, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Atrial Fibrillation is KCNQ1 (Potassium Voltage-Gated Channel Subfamily Q Member 1), and among its related pathways/superpathways are Vascular smooth muscle contraction and Adrenergic signaling in cardiomyocytes. The drugs Atorvastatin and Amiodarone have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and testes, and related phenotypes are no effect and cardiovascular system

Disease Ontology : 12 A heart conduction disease that is characterized by uncoordinated electrical activity in the heart's upper chambers (the atria), which causes the heartbeat to become fast and irregular and has symptoms palpitations, weakness, fatigue, lightheadedness, dizziness, confusion, shortness of breath and chest pain.

MedlinePlus : 44 An arrhythmia is a problem with the speed or rhythm of the heartbeat. Atrial fibrillation (AF) is the most common type of arrhythmia. The cause is a disorder in the heart's electrical system. Often, people who have AF may not even feel symptoms. But you may feel Palpitations -- an abnormal rapid heartbeat Shortness of breath Weakness or difficulty exercising Chest pain Dizziness or fainting Fatigue Confusion AF can lead to an increased risk of stroke. In many patients, it can also cause chest pain, heart attack, or heart failure. Doctors diagnose AF using family and medical history, a physical exam, and a test called an electrocardiogram (EKG), which looks at the electrical waves your heart makes. Treatments include medicines and procedures to restore normal rhythm. NIH: National Heart, Lung, and Blood Institute

CDC : 3 Electrical activity of a normal heart (left) and a heart with atrial fibrillation (right).

Wikipedia : 77 Atrial fibrillation (AF or A-fib) is an abnormal heart rhythm characterized by rapid and irregular... more...

Related Diseases for Atrial Fibrillation

Diseases in the Atrial Fibrillation family:

Atrial Fibrillation, Familial, 3 Atrial Fibrillation, Familial, 1
Atrial Fibrillation, Familial, 2 Atrial Fibrillation, Familial, 4
Atrial Fibrillation, Familial, 5 Atrial Fibrillation, Familial, 6
Atrial Fibrillation, Familial, 7 Atrial Fibrillation, Familial, 8
Atrial Fibrillation, Familial, 9 Atrial Fibrillation, Familial, 10
Atrial Fibrillation, Familial, 11 Atrial Fibrillation, Familial, 12
Atrial Fibrillation, Familial, 13 Atrial Fibrillation, Familial, 14
Atrial Fibrillation, Familial, 15 Atrial Fibrillation, Familial, 18
Familial Atrial Fibrillation

Diseases related to Atrial Fibrillation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 520)
# Related Disease Score Top Affiliating Genes
1 familial atrial fibrillation 34.0 ABCC9 GJA5 KCNA5 KCNE2 KCNH2 KCNJ2
2 congestive heart failure 31.7 ACE ADRB1 NPPA NPPB
3 mitral valve insufficiency 31.6 ACE NPPA NPPB
4 heart valve disease 31.6 ACE NPPA NPPB
5 progressive familial heart block, type ia 31.5 GJA5 SCN5A
6 atrioventricular block 31.4 KCNE2 KCNH2 KCNQ1 NPPB SCN5A
7 cardiac conduction defect 31.4 KCNH2 KCNQ1 SCN5A
8 myocardial infarction 31.4 ABCC9 ACE ADRB1 NPPA NPPB
9 ventricular fibrillation, paroxysmal familial, 1 31.4 KCNE2 KCNH2 KCNQ1 SCN5A
10 third-degree atrioventricular block 31.2 KCNE2 NPPB SCN5A
11 coronary artery anomaly 31.2 ACE ADRB1 NPPA NPPB
12 left bundle branch hemiblock 31.2 ACE NPPB SCN5A
13 atrial standstill 1 31.2 ACE ADRB1 GJA5 NPPB SCN1B SCN5A
14 acute myocardial infarction 31.2 ACE ADRB1 NPPA NPPB
15 syncope 31.1 KCNH2 KCNJ2 KCNQ1 NPPA NPPB SCN5A
16 systolic heart failure 31.1 ACE ADRB1 NPPB
17 heart disease 31.0 ACE ADRB1 GJA5 KCNE2 KCNH2 KCNJ2
18 right bundle branch block 31.0 SCN1B SCN2B SCN3B SCN5A
19 cardiac arrhythmia 30.9 KCNE2 KCNH2 KCNJ2 KCNQ1 SCN5A
20 brugada syndrome 30.9 ABCC9 KCNA5 KCNE2 KCNH2 KCNQ1 SCN1B
21 short qt syndrome 30.9 KCNE2 KCNH2 KCNJ2 KCNQ1
22 hypertension, essential 30.8 ACE ADRB1 NPPA NPPB
23 cardiac arrest 30.8 ACE KCNH2 KCNQ1 NPPB SCN5A
24 aortic valve disease 2 30.8 ACE MYL4 NPPA NPPB
25 pulmonary hypertension 30.8 ACE KCNA5 NPPA NPPB
26 diastolic heart failure 30.7 ACE NPPA NPPB
27 central sleep apnea 30.7 NPPA NPPB
28 catecholaminergic polymorphic ventricular tachycardia 30.7 KCNH2 KCNJ2 SCN5A
29 coronary heart disease 1 30.7 ACE ADRB1 NPPB
30 tetralogy of fallot 30.6 GJA5 KCNH2 NPPA NPPB
31 pulmonary edema 30.6 ACE NPPA NPPB
32 atrial standstill 30.5 GJA5 NPPA SCN5A
33 long qt syndrome 1 30.5 KCNE2 KCNH2 KCNJ2 KCNQ1 SCN4B SCN5A
34 chagas disease 30.5 ACE ADRB1 NPPB
35 dilated cardiomyopathy 30.4 ABCC9 ACE ADRB1 GJA5 KCNH2 KCNQ1
36 brugada syndrome 1 30.3 KCNA5 KCNH2 SCN5A
37 anterolateral myocardial infarction 30.3 ACE NPPA NPPB
38 long qt syndrome 30.3 ADRB1 KCNA5 KCNE2 KCNH2 KCNJ2 KCNQ1
39 first-degree atrioventricular block 30.3 GJA5 SCN5A
40 sudden infant death syndrome 30.1 KCNH2 KCNQ1 SCN2B SCN3B SCN4B SCN5A
41 timothy syndrome 30.0 KCNH2 KCNQ1
42 atrial fibrillation, familial, 15 12.8
43 atrial fibrillation, familial, 3 12.8
44 atrial fibrillation, familial, 11 12.8
45 atrial fibrillation, familial, 7 12.8
46 atrial fibrillation, familial, 6 12.8
47 atrial fibrillation, familial, 10 12.8
48 atrial fibrillation, familial, 4 12.8
49 atrial fibrillation, familial, 9 12.8
50 atrial fibrillation, familial, 12 12.8

Graphical network of the top 20 diseases related to Atrial Fibrillation:



Diseases related to Atrial Fibrillation

Symptoms & Phenotypes for Atrial Fibrillation

UMLS symptoms related to Atrial Fibrillation:


angina pectoris, edema, chest pain

GenomeRNAi Phenotypes related to Atrial Fibrillation according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ABCC9 ACE ADRB1 GJA5 KCNA5 KCNE2

MGI Mouse Phenotypes related to Atrial Fibrillation:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 ABCC9 ACE ADRB1 GJA5 KCNA5 KCNH2
2 homeostasis/metabolism MP:0005376 9.8 ABCC9 ACE ADRB1 GJA5 KCNA5 KCNE2
3 muscle MP:0005369 9.28 ABCC9 ADRB1 GJA5 KCNA5 KCNH2 KCNJ2

Drugs & Therapeutics for Atrial Fibrillation

PubMedHealth treatment related to Atrial Fibrillation: 64

Treatment for atrial fibrillation (AF) depends on how often you have symptoms, how severe they are, and whether you already have heart disease. General treatment options include medicines, medical procedures, and lifestyle changes.

Drugs for Atrial Fibrillation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 636)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 134523-00-5 60823
2
Amiodarone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 1951-25-3 2157
3
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1401-55-4
4
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
5
Warfarin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81-81-2 54678486 6691
6
Apixaban Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 503612-47-3 10182969
7
Rivaroxaban Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 366789-02-8
8
Propafenone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54063-53-5 4932
9
Sotalol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 959-24-0, 3930-20-9 5253
10
Carvedilol Approved, Investigational Phase 4,Phase 3,Not Applicable 72956-09-3 2585
11
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 37350-58-6, 51384-51-1 4171
12
Dronedarone Approved Phase 4,Phase 3,Phase 2,Not Applicable 141626-36-0, 141625-93-6 154087
13
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
14
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Not Applicable 120202-66-6, 113665-84-2 60606
15
Ticagrelor Approved Phase 4,Phase 3,Phase 1 274693-27-5 9871419
16
Diltiazem Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 42399-41-7 39186
17 Menaquinone Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 1182-68-9
18
Edoxaban Approved Phase 4,Phase 3,Phase 2,Not Applicable 480449-70-5
19
Phylloquinone Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 84-80-0
20
Irbesartan Approved, Investigational Phase 4,Phase 3 138402-11-6 3749
21
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198
22
carbamide peroxide Approved Phase 4,Not Applicable 124-43-6
23
Acenocoumarol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 152-72-7 54676537 9052
24
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3 69-72-7 338
25
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3 302-25-0
26
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
27
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
28
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3 2921-57-5
29
Phenprocoumon Approved, Investigational Phase 4,Phase 3 435-97-2 54680692 9908
30
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
31
Dalteparin Approved Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6
32 fluindione Approved, Investigational Phase 4,Phase 3 957-56-2
33
Amlodipine Approved Phase 4,Not Applicable 88150-42-9 2162
34
Amiloride Approved Phase 4 2609-46-3, 2016-88-8 16231
35
Telmisartan Approved, Investigational Phase 4,Not Applicable 144701-48-4 65999
36
Simvastatin Approved Phase 4,Phase 2,Not Applicable 79902-63-9 54454
37
Ranolazine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 95635-55-5, 142387-99-3 56959
38
Metronidazole Approved Phase 4,Not Applicable 443-48-1 4173
39
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
40
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
41
Candesartan cilexetil Approved Phase 4,Phase 3 145040-37-5 2540
42
Captopril Approved Phase 4,Not Applicable 62571-86-2 44093
43
Bisoprolol Approved Phase 4,Early Phase 1,Not Applicable 66722-44-9 2405
44
Ramipril Approved Phase 4,Phase 2,Phase 3,Not Applicable 87333-19-5 5362129
45
Enalaprilat Approved Phase 4,Phase 3,Not Applicable 76420-72-9 6917719
46
Spironolactone Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 1952-01-7, 52-01-7 5833
47
Nebivolol Approved, Investigational Phase 4,Not Applicable 152520-56-4, 99200-09-6, 118457-14-0 71301
48
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 137862-53-4 60846
49
Enalapril Approved, Vet_approved Phase 4,Phase 3,Not Applicable 75847-73-3 40466924 5362032
50
Eplerenone Approved Phase 4,Phase 3,Phase 2 107724-20-9 443872 150310

Interventional clinical trials:

(show top 50) (show all 2706)
# Name Status NCT ID Phase Drugs
1 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Impaired Left Ventricular Function Unknown status NCT02509754 Phase 4
2 Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF) Unknown status NCT02029534 Phase 4 Atorvastatin 20 mg;Atorvastatin 80 mg
3 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer Unknown status NCT00724581 Phase 4 Amiodarone
4 Cardioversion vs. Catheter Ablation for Persistent Atrial Fibrillation Unknown status NCT00196209 Phase 4
5 The Effect of Chest Tubes Using Active Clearance Technology® on the Incidence of Postoperative Atrial Fibrillation Unknown status NCT02808897 Phase 4
6 Additional Linear Ablation Beyond Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation Unknown status NCT02637453 Phase 4
7 AF Ablation With or Without ROX Coupler Study Unknown status NCT02243891 Phase 4
8 Line Versus Spot Ablation in Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
9 AMIOdarone vs. Catheter Ablation for Prevention of Recurrent Symptomatic Atrial Fibrillation Unknown status NCT02341105 Phase 4 Amiodarone
10 The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients Unknown status NCT02646267 Phase 4 standard intensity warfarin;low intensity warfarin;dabigatran etexilate
11 Left Atrial Ablation of Paroxysmal Atrial Fibrillation With Implantable Loop Recorder Follow Up Study: The LAAPITUP 2 Study Unknown status NCT01504451 Phase 4
12 Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation Unknown status NCT02666157 Phase 4 Dabigatran etexilate;Rivaroxaban;Apixaban
13 Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
14 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
15 Graz Study on the Risk of Atrial Fibrillation Unknown status NCT01461434 Phase 4
16 Rate Control in Atrial Fibrillation Unknown status NCT02251509 Phase 4 Carvedilol;Metoprolol tartrate
17 Vernakalant Versus Flecainide: Atrial Contractility Unknown status NCT01646281 Phase 4 Vernakalant;Flecainide
18 Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China Unknown status NCT01341353 Phase 4 Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists
19 Efficacy and Safety Study of Catheter Ablation for Atrial Fibrillation Unknown status NCT01113294 Phase 4
20 Dronedarone in Pacemakers Patients With Paroxysmal Atrial Fibrillation Unknown status NCT01070667 Phase 4 Dronedarone;Placebo
21 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
22 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
23 Pulmonary Vein (PV) -Isolation: Arrhythmogenic Vein(s) Versus All Veins Unknown status NCT00605748 Phase 4
24 Low Dose of Diltiazem for Rate Control of Atrial Fibrillation Unknown status NCT00834925 Phase 4 low dose diltiazem
25 Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban Unknown status NCT02549963 Phase 4 Rivaroxaban
26 Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran Unknown status NCT02331602 Phase 4 Rivaroxaban;Dabigatran
27 Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation Unknown status NCT02475642 Phase 4
28 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
29 A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy Unknown status NCT00773539 Phase 4
30 ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON) Unknown status NCT02935855 Phase 4 Dabigatran;Apixaban;Rivaroxaban;Edoxaban;Warfarin;Acenocumarole
31 EvaluAtion of Predictive Value of Multisite Intracardiac EchoCardiography During Imaging of Structure and funCTION of Left Atrial Appendage in Comparison to Transesophageal Echocardiography Unknown status NCT01371279 Phase 4
32 Comparison Between Contact Force Guided and Blinded Strategy on PV Isolation in AF Patients Unknown status NCT02924181 Phase 4
33 Irbesartan and Adhesion Molecules in AF Unknown status NCT00613496 Phase 4 irbesartan;placebo
34 Anticoagulation in Stent Intervention Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
35 Corticosteroid Pulse After Ablation Unknown status NCT00807586 Phase 4 Solumedrol;Placebo
36 Mode Evaluation in Sick Sinus Syndrome Trial (MODEST) Unknown status NCT00161551 Phase 4
37 Left Atrial Thrombus Reduction - Effect of Dabigatran Versus Phenprocoumon Unknown status NCT02591225 Phase 4 Dabigatranetexilate;Phenprocoumon
38 Safety of "Ticagrelor+ Warfarin"in Comparison With "Clopidogrel+Aspirin+Warfarin" Unknown status NCT02206815 Phase 4 Ticagrelor+Warfarin;Clopidogrel+Aspirin+Warfarin
39 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
40 Catheter Contact Force and Electrograms Unknown status NCT01587404 Phase 4
41 Ventricular Pacing Site Selection (V-PASS) Unknown status NCT00292383 Phase 4
42 Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF Unknown status NCT02256683 Phase 4 Dabigatran etexilate;Phenprocoumon
43 SmartTouch Catheter for Left Anterior Line - SmarT Line Study Unknown status NCT02217657 Phase 4
44 The Efficacy and Safety of CARTO 3D Mapping System Versus Conventional Method in AF and VT Unknown status NCT00959205 Phase 4
45 Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation Unknown status NCT00776633 Phase 4 aspirin;clopidogrel;oral anticoagulation
46 Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
47 Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation Unknown status NCT02161965 Phase 4 Rivaroxaban;Fluindione;Warfarin
48 RAAS Inhibitor Drugs in Dialysis Patients Unknown status NCT01635387 Phase 4 aliskiren
49 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
50 Right Ventricular Septal Pacing for the Prevention of Left Ventricular Dysfunction in Patients With Atrio-Ventricular Block Unknown status NCT00709774 Phase 4

Search NIH Clinical Center for Atrial Fibrillation

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: atrial fibrillation

Genetic Tests for Atrial Fibrillation

Genetic tests related to Atrial Fibrillation:

# Genetic test Affiliating Genes
1 Atrial Fibrillation 30

Anatomical Context for Atrial Fibrillation

MalaCards organs/tissues related to Atrial Fibrillation:

42
Heart, Kidney, Testes, Lung, Brain, Liver, Endothelial

Publications for Atrial Fibrillation

Articles related to Atrial Fibrillation:

(show top 50) (show all 7446)
# Title Authors Year
1
Poor adherence to guideline recommendations among patients with atrial fibrillation and acute myocardial infarction. ( 30966816 )
2019
2
Galectin-3 in Acute Myocardial Infarction Patients with Atrial Fibrillation. ( 30726858 )
2019
3
Acute myocardial infarction associated with bilateral subacute cardioembolic stroke in the anterior cerebral artery territory: The hidden face of a new-onset atrial fibrillation. ( 27650538 )
2019
4
Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. ( 30753432 )
2019
5
A case report of atrial fibrillation in a patient with heparin resistance associated with an antithrombin III deficiency successfully treated by radiofrequency catheter ablation using a direct thrombin inhibitor. ( 31020242 )
2019
6
Case 9-2019: A 62-Year-Old Man with Atrial Fibrillation, Depression, and Worsening Anxiety. ( 30893540 )
2019
7
Triggers for Atrial Fibrillation: The Role of Anxiety. ( 30906592 )
2019
8
Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis. ( 30916734 )
2019
9
Pharmacotherapy for Patients With Atrial Fibrillation and Cerebral Microbleeds. ( 31103554 )
2019
10
Effectiveness and Safety of Four Direct Oral Anticoagulants in Asians with Non-valvular Atrial Fibrillation. ( 31103697 )
2019
11
Feasibility and safety of uninterrupted apixaban in patients undergoing radiofrequency ablation for atrial fibrillation. ( 31104262 )
2019
12
Catheter ablation for lone atrial fibrillation in individuals aged under 35 years. ( 31104644 )
2019
13
Application of nonlinear methods to discriminate fractionated electrograms in paroxysmal versus persistent atrial fibrillation. ( 31104705 )
2019
14
Impaired coronary blood flow at higher heart rates during atrial fibrillation: Investigation via multiscale modelling. ( 31104719 )
2019
15
Clinical Outcomes of Antithrombotic Strategies for Patients with Atrial Fibrillation After Percutaneous Coronary Intervention. ( 31105152 )
2019
16
Multifractal Desynchronization of the Cardiac Excitable Cell Network During Atrial Fibrillation. II. Modeling. ( 31105585 )
2019
17
Harnessing big data for identifying atrial fibrillation. ( 31106348 )
2019
18
Long-term outcomes of pulmonary vein isolation using second-generation cryoballoon during atrial fibrillation ablation. ( 31106431 )
2019
19
Improvement of peripheral microcirculation after cardioversion of atrial fibrillation. ( 31106433 )
2019
20
Electrical cardioversion of atrial fibrillation improves peripheral microcirculation. ( 31107545 )
2019
21
Hyoscyamine for a Slow Ventricular Response During Atrial Fibrillation. ( 31108526 )
2019
22
Hyoscyamine for a Slow Ventricular Response During Atrial Fibrillation. ( 31108527 )
2019
23
Triple versus dual oral antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and meta-analysis. ( 31109394 )
2019
24
Meta-analysis of Atrial Fibrillation in Patients With Various Cardiomyopathies. ( 31109634 )
2019
25
Sarcopenia, frailty, cognitive impairment and mortality in elderly patients with non-valvular atrial fibrillation. ( 31109685 )
2019
26
Increased plasma microfibrillar-associated protein 4 is associated with atrial fibrillation and more advanced left atrial remodelling. ( 31110528 )
2019
27
Acute breathlessness with frank hemoptysis following catheter ablation for atrial fibrillation, a cause not so obvious. ( 31110703 )
2019
28
Use of wearable cardioverter-defibrillator in association with catheter ablation for atrial fibrillation-related tachycardiomyopathy. ( 31110733 )
2019
29
Association of Cancer and the Risk of Developing Atrial Fibrillation: A Systematic Review and Meta-Analysis. ( 31110819 )
2019
30
Comparative effectiveness of rivaroxaban versus a vitamin K antagonist in patients with renal impairment treated for non-valvular atrial fibrillation in Germany - A retrospective cohort study. ( 31111087 )
2019
31
Double Jeopardy: Will the new trials tell us how to manage patients with atrial fibrillation and coronary artery disease? ( 31111088 )
2019
32
Anticoagulation Resumption After Stroke from Atrial Fibrillation. ( 31111239 )
2019
33
Creatinine monitoring patterns in the setting of direct oral anticoagulant therapy for non-valvular atrial fibrillation. ( 31111434 )
2019
34
Left Atrial Effective Conducting Size Predicts Atrial Fibrillation Vulnerability in Persistent but not Paroxysmal Atrial Fibrillation. ( 31111557 )
2019
35
Effectiveness of Dual External Direct Current Cardioversion for Initial Cardioversion in Atrial Fibrillation. ( 31111594 )
2019
36
Patient involvement in consultation for atrial fibrillation - the cardiologists' perspective. ( 31111778 )
2019
37
Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients. ( 31112292 )
2019
38
Short lookback periods causing exaggerated stroke risk estimates in atrial fibrillation may expose patients to unnecessary anticoagulant treatment. ( 31112361 )
2019
39
Acute renal and splenic infarctions as the initial manifestations of atrial fibrillation. ( 31057170 )
2019
40
Exploring the Mechanism of Effectiveness of a Psychoeducational Intervention in a Rehabilitation Program (CopenHeartRFA) for Patients Treated With Ablation for Atrial Fibrillation: A Mixed Methods Study. ( 31058705 )
2019
41
Genetic variant in the promoter region of microRNA‑137 reduces the warfarin maintenance dose in patients with atrial fibrillation. ( 31059093 )
2019
42
Quantitative proteomics of changes in succinylated proteins expression profiling in left appendages tissue from valvular heart disease patients with atrial fibrillation. ( 31059701 )
2019
43
Correction: Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure. ( 31060071 )
2019
44
Atrial Fibrillation and End-Stage COPD: A Close Association Revisited. ( 31060700 )
2019
45
Thromboembolism in the Absence of Atrial Fibrillation. ( 31060729 )
2019
46
Embolic stroke of undetermined source: Beyond atrial fibrillation. ( 31060753 )
2019
47
Atrial Fibrillation Does Not Matter in Japanese Ventricular Assist Device Patients? - Half-Way Up the Hill. ( 31061354 )
2019
48
Biomarkers of Atrial Fibrillation: Which One Is a True Marker? ( 31061732 )
2019
49
Routine Detection of Atrial Fibrillation/Flutter Predicts a Worse Outcome in a Cohort of Tetralogy of Fallot Patients During 23 Years of Follow-Up. ( 31062060 )
2019
50
Antithrombotic treatment patterns and stroke prevention in patients with atrial fibrillation in TURKEY: inferences from GARFIELD-AF registry. ( 31062761 )
2019

Variations for Atrial Fibrillation

ClinVar genetic disease variations for Atrial Fibrillation:

6 (show all 42)
# Gene Variation Type Significance SNP ID Assembly Location
1 KCNQ1 NM_000218.2(KCNQ1): c.418A> G (p.Ser140Gly) single nucleotide variant Pathogenic rs120074192 GRCh37 Chromosome 11, 2549189: 2549189
2 KCNQ1 NM_000218.2(KCNQ1): c.418A> G (p.Ser140Gly) single nucleotide variant Pathogenic rs120074192 GRCh38 Chromosome 11, 2527959: 2527959
3 KCNE2 NM_172201.1(KCNE2): c.79C> T (p.Arg27Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs74315449 GRCh37 Chromosome 21, 35742856: 35742856
4 KCNE2 NM_172201.1(KCNE2): c.79C> T (p.Arg27Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs74315449 GRCh38 Chromosome 21, 34370557: 34370557
5 SCN5A NM_000335.4(SCN5A): c.5958C> A (p.Asn1986Lys) single nucleotide variant Uncertain significance rs199473335 GRCh37 Chromosome 3, 38591902: 38591902
6 SCN5A NM_000335.4(SCN5A): c.5958C> A (p.Asn1986Lys) single nucleotide variant Uncertain significance rs199473335 GRCh38 Chromosome 3, 38550411: 38550411
7 SCN5A NM_198056.2(SCN5A): c.1333C> G (p.His445Asp) single nucleotide variant Uncertain significance rs199473112 GRCh37 Chromosome 3, 38647447: 38647447
8 SCN5A NM_198056.2(SCN5A): c.1333C> G (p.His445Asp) single nucleotide variant Uncertain significance rs199473112 GRCh38 Chromosome 3, 38605956: 38605956
9 SCN5A NM_000335.4(SCN5A): c.1410C> G (p.Asn470Lys) single nucleotide variant Pathogenic rs199473115 GRCh37 Chromosome 3, 38646328: 38646328
10 SCN5A NM_000335.4(SCN5A): c.1410C> G (p.Asn470Lys) single nucleotide variant Pathogenic rs199473115 GRCh38 Chromosome 3, 38604837: 38604837
11 SCN5A NM_000335.4(SCN5A): c.1282G> A (p.Glu428Lys) single nucleotide variant Uncertain significance rs199473111 GRCh37 Chromosome 3, 38647498: 38647498
12 SCN5A NM_000335.4(SCN5A): c.1282G> A (p.Glu428Lys) single nucleotide variant Uncertain significance rs199473111 GRCh38 Chromosome 3, 38606007: 38606007
13 SCN5A NM_198056.2(SCN5A): c.1963G> A (p.Glu655Lys) single nucleotide variant Likely pathogenic rs199473579 GRCh37 Chromosome 3, 38640469: 38640469
14 SCN5A NM_198056.2(SCN5A): c.1963G> A (p.Glu655Lys) single nucleotide variant Likely pathogenic rs199473579 GRCh38 Chromosome 3, 38598978: 38598978
15 KCNJ2 NM_000891.2(KCNJ2): c.277G> A (p.Val93Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs147750704 GRCh37 Chromosome 17, 68171457: 68171457
16 KCNJ2 NM_000891.2(KCNJ2): c.277G> A (p.Val93Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs147750704 GRCh38 Chromosome 17, 70175316: 70175316
17 SCN5A NM_000335.4(SCN5A): c.5848G> T (p.Val1950Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs41315493 GRCh37 Chromosome 3, 38592012: 38592012
18 SCN5A NM_000335.4(SCN5A): c.5848G> T (p.Val1950Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs41315493 GRCh38 Chromosome 3, 38550521: 38550521
19 KCNQ1 NM_000218.2(KCNQ1): c.421G> A (p.Val141Met) single nucleotide variant Pathogenic/Likely pathogenic rs199472687 GRCh37 Chromosome 11, 2549192: 2549192
20 KCNQ1 NM_000218.2(KCNQ1): c.421G> A (p.Val141Met) single nucleotide variant Pathogenic/Likely pathogenic rs199472687 GRCh38 Chromosome 11, 2527962: 2527962
21 KCNQ1 NM_000218.2(KCNQ1): c.440A> G (p.Gln147Arg) single nucleotide variant not provided rs199472689 GRCh37 Chromosome 11, 2549211: 2549211
22 KCNQ1 NM_000218.2(KCNQ1): c.440A> G (p.Gln147Arg) single nucleotide variant not provided rs199472689 GRCh38 Chromosome 11, 2527981: 2527981
23 KCNQ1 NM_000218.2(KCNQ1): c.625T> C (p.Ser209Pro) single nucleotide variant Pathogenic rs199472705 GRCh37 Chromosome 11, 2592575: 2592575
24 KCNQ1 NM_000218.2(KCNQ1): c.625T> C (p.Ser209Pro) single nucleotide variant Pathogenic rs199472705 GRCh38 Chromosome 11, 2571345: 2571345
25 KCNH2 NM_000238.3(KCNH2): c.2690A> C (p.Lys897Thr) single nucleotide variant Benign/Likely benign rs1805123 GRCh37 Chromosome 7, 150645534: 150645534
26 KCNH2 NM_000238.3(KCNH2): c.2690A> C (p.Lys897Thr) single nucleotide variant Benign/Likely benign rs1805123 GRCh38 Chromosome 7, 150948446: 150948446
27 KCNE2 NM_172201.1(KCNE2): c.269A> G (p.Glu90Gly) single nucleotide variant not provided rs199473366 GRCh37 Chromosome 21, 35743046: 35743046
28 KCNE2 NM_172201.1(KCNE2): c.269A> G (p.Glu90Gly) single nucleotide variant not provided rs199473366 GRCh38 Chromosome 21, 34370747: 34370747
29 SCN5A NM_198056.2(SCN5A): c.3392C> T (p.Thr1131Ile) single nucleotide variant Uncertain significance rs199473197 GRCh37 Chromosome 3, 38618271: 38618271
30 SCN5A NM_198056.2(SCN5A): c.3392C> T (p.Thr1131Ile) single nucleotide variant Uncertain significance rs199473197 GRCh38 Chromosome 3, 38576780: 38576780
31 SCN5A NM_000335.4(SCN5A): c.414G> A (p.Met138Ile) single nucleotide variant Uncertain significance rs199473060 GRCh37 Chromosome 3, 38663959: 38663959
32 SCN5A NM_000335.4(SCN5A): c.414G> A (p.Met138Ile) single nucleotide variant Uncertain significance rs199473060 GRCh38 Chromosome 3, 38622468: 38622468
33 SCN5A NM_198056.2(SCN5A): c.4478A> G (p.Lys1493Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs199473260 GRCh37 Chromosome 3, 38597211: 38597211
34 SCN5A NM_198056.2(SCN5A): c.4478A> G (p.Lys1493Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs199473260 GRCh38 Chromosome 3, 38555720: 38555720
35 SCN5A NM_198056.2(SCN5A): c.5476C> T (p.Arg1826Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs199473635 GRCh37 Chromosome 3, 38592387: 38592387
36 SCN5A NM_198056.2(SCN5A): c.5476C> T (p.Arg1826Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs199473635 GRCh38 Chromosome 3, 38550896: 38550896
37 SCN5A NM_198056.2(SCN5A): c.5624T> C (p.Met1875Thr) single nucleotide variant Likely pathogenic rs199473324 GRCh37 Chromosome 3, 38592239: 38592239
38 SCN5A NM_198056.2(SCN5A): c.5624T> C (p.Met1875Thr) single nucleotide variant Likely pathogenic rs199473324 GRCh38 Chromosome 3, 38550748: 38550748
39 SCN5A NM_198056.2(SCN5A): c.5851G> A (p.Val1951Met) single nucleotide variant Conflicting interpretations of pathogenicity rs41315493 GRCh37 Chromosome 3, 38592012: 38592012
40 SCN5A NM_198056.2(SCN5A): c.5851G> A (p.Val1951Met) single nucleotide variant Conflicting interpretations of pathogenicity rs41315493 GRCh38 Chromosome 3, 38550521: 38550521
41 MYH7 NM_000257.4(MYH7): c.5190G> T (p.Met1730Ile) single nucleotide variant Uncertain significance GRCh38 Chromosome 14, 23415474: 23415474
42 MYH7 NM_000257.4(MYH7): c.5190G> T (p.Met1730Ile) single nucleotide variant Uncertain significance GRCh37 Chromosome 14, 23884683: 23884683

Expression for Atrial Fibrillation

Search GEO for disease gene expression data for Atrial Fibrillation.

Pathways for Atrial Fibrillation

Pathways related to Atrial Fibrillation according to KEGG:

38
# Name Kegg Source Accession
1 Vascular smooth muscle contraction hsa04270
2 Adrenergic signaling in cardiomyocytes hsa04261

Pathways related to Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.87 ADRB1 GJA5 SCN1B SCN2B SCN3B SCN4B
2
Show member pathways
12.82 ADRB1 KCNQ1 MYL4 SCN1B SCN4B SCN5A
3
Show member pathways
12.5 SCN1B SCN2B SCN3B SCN4B SCN5A
4
Show member pathways
12.46 ABCC9 KCNE2 KCNH2 KCNJ2 KCNQ1 MYL4
5 12.38 ADRB1 SCN1B SCN2B SCN5A
6 12.19 KCNA5 KCNE2 KCNH2 KCNJ2 KCNQ1
7
Show member pathways
12.01 ADRB1 KCNE2 KCNJ2 KCNQ1
8 12.01 KCNH2 KCNQ1 SCN3B SCN4B SCN5A
9
Show member pathways
11.94 ABCC9 KCNA5 KCNH2 KCNJ2 KCNQ1
10
Show member pathways
11.82 SCN1B SCN2B SCN3B SCN4B SCN5A
11
Show member pathways
11.57 KCNE2 KCNQ1 SCN1B SCN2B SCN3B SCN4B
12 11.54 ACE ADRB1 KCNJ2
13 11.18 ABCC9 ADRB1 GJA5 KCNA5 KCNE2 KCNH2
14 11.13 SCN1B SCN2B SCN3B SCN4B SCN5A
15 10.9 NPPA NPPB
16 10.82 KCNJ2 KCNQ1

GO Terms for Atrial Fibrillation

Cellular components related to Atrial Fibrillation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Z disc GO:0030018 9.61 KCNA5 SCN3B SCN5A
2 voltage-gated potassium channel complex GO:0008076 9.55 KCNA5 KCNE2 KCNH2 KCNJ2 KCNQ1
3 T-tubule GO:0030315 9.5 KCNJ2 SCN1B SCN5A
4 intercalated disc GO:0014704 9.43 GJA5 KCNA5 KCNJ2 SCN1B SCN4B SCN5A
5 voltage-gated sodium channel complex GO:0001518 9.02 SCN1B SCN2B SCN3B SCN4B SCN5A
6 membrane GO:0016020 10.27 ABCC9 ACE ADRB1 GJA5 KCNA5 KCNE2
7 plasma membrane GO:0005886 10.22 ABCC9 ACE ADRB1 GJA5 KCNA5 KCNE2
8 integral component of membrane GO:0016021 10.13 ABCC9 ACE ADRB1 GJA5 KCNA5 KCNE2

Biological processes related to Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 48)
# Name GO ID Score Top Affiliating Genes
1 sodium ion transmembrane transport GO:0035725 9.97 SCN1B SCN2B SCN3B SCN4B SCN5A
2 regulation of ion transmembrane transport GO:0034765 9.96 KCNA5 KCNE2 KCNH2 KCNJ2 KCNQ1 SCN1B
3 ventricular cardiac muscle cell action potential GO:0086005 9.88 GJA5 KCNE2 KCNH2 KCNQ1 SCN3B SCN5A
4 regulation of sodium ion transmembrane transporter activity GO:2000649 9.87 SCN1B SCN2B SCN3B SCN4B
5 cellular response to drug GO:0035690 9.86 KCNE2 KCNH2 KCNQ1
6 positive regulation of sodium ion transport GO:0010765 9.86 SCN1B SCN3B SCN4B SCN5A
7 regulation of blood pressure GO:0008217 9.85 ACE NPPA NPPB
8 potassium ion export across plasma membrane GO:0097623 9.85 KCNA5 KCNE2 KCNH2 KCNQ1
9 regulation of atrial cardiac muscle cell membrane depolarization GO:0060371 9.85 GJA5 SCN1B SCN2B SCN3B SCN5A
10 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.85 KCNJ2 SCN1B SCN2B SCN3B SCN4B SCN5A
11 potassium ion import across plasma membrane GO:1990573 9.84 ABCC9 KCNE2 KCNJ2
12 regulation of membrane repolarization GO:0060306 9.84 KCNE2 KCNH2 KCNJ2 KCNQ1
13 membrane depolarization GO:0051899 9.83 SCN1B SCN3B SCN5A
14 membrane repolarization during action potential GO:0086011 9.83 KCNE2 KCNH2 KCNJ2 KCNQ1
15 atrial cardiac muscle cell action potential GO:0086014 9.83 KCNA5 KCNQ1 NUP155 SCN3B SCN5A
16 positive regulation of heart rate GO:0010460 9.82 KCNQ1 NPPA SCN3B
17 membrane depolarization during action potential GO:0086010 9.82 KCNH2 SCN3B SCN5A
18 positive regulation of potassium ion transmembrane transport GO:1901381 9.81 KCNH2 KCNJ2 KCNQ1
19 regulation of blood vessel diameter GO:0097746 9.81 ACE GJA5 NPPB
20 cardiac conduction GO:0061337 9.8 GJA5 SCN1B SCN3B
21 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.8 KCNE2 KCNH2 KCNQ1
22 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.8 KCNA5 KCNQ1 NPPA SCN5A
23 membrane repolarization GO:0086009 9.79 KCNE2 KCNH2 KCNQ1
24 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.79 KCNH2 KCNJ2 KCNQ1
25 regulation of ventricular cardiac muscle cell membrane depolarization GO:0060373 9.77 GJA5 SCN3B SCN5A
26 SA node cell action potential GO:0086015 9.76 GJA5 SCN3B SCN5A
27 cardiac muscle contraction GO:0060048 9.76 KCNH2 KCNQ1 MYL4 SCN1B SCN2B SCN3B
28 regulation of vasoconstriction GO:0019229 9.7 ACE KCNA5
29 regulation of potassium ion transmembrane transport GO:1901379 9.7 KCNE2 KCNH2
30 regulation of blood vessel size GO:0050880 9.7 NPPA NPPB
31 potassium ion homeostasis GO:0055075 9.7 KCNA5 KCNH2
32 regulation of cardiac muscle cell contraction GO:0086004 9.69 KCNJ2 SCN5A
33 cGMP biosynthetic process GO:0006182 9.69 NPPA NPPB
34 positive regulation of cardiac muscle contraction GO:0060452 9.69 KCNQ1 NPPA
35 receptor guanylyl cyclase signaling pathway GO:0007168 9.68